Related Experiment Videos
The choice of treatment in polycythaemia vera
Abstract:
The current results of prospective protocols initiated by the Polycythaemia Vera Study Group are presented. These results help to define the best choice of treatment in accordance with the risk factors.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
TCRBV3S1 and TCRBV18 gene segment polymorphisms in Brazilian Caucasoid and Black populations.
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics·2002
[Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
Annales de medecine interne·2001
A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
Drugs under experimental and clinical research·2006
Psychiatric factors in patients with sensitive skin.
Drugs under experimental and clinical research·2006
Objective biophysical findings in patients with sensitive skin.
Drugs under experimental and clinical research·2006
Is itraconazole the treatment of choice in Microsporum canis tinea capitis?
Drugs under experimental and clinical research·2006
Improvement of otitis media with effusion after treatment of asthma with leukotriene antagonists in children with co-existing disease.
Drugs under experimental and clinical research·2006
Twice-daily dosing of loracarbef 15 mg/kg versus 30 mg/kg in the treatment of children with acute sinusitis.
Drugs under experimental and clinical research·2006
Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease.
Drug design, development and therapy·2026
PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines.
Molecular therapy. Nucleic acids·2026
miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.
Molecular therapy. Nucleic acids·2026